- Home
- URGN vs EE Comparison
URGN vs EE Comparison
Compare URGN & EE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- EE
- Stock Information
- Founded
- URGN 2004
- EE 2003
- Country
- URGN United States
- EE United States
- Employees
- URGN N/A
- EE N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- EE Oil/Gas Transmission
- Sector
- URGN Health Care
- EE Utilities
- Exchange
- URGN Nasdaq
- EE Nasdaq
- Market Cap
- URGN 896.3M
- EE 786.2M
- IPO Year
- URGN 2017
- EE 2022
- Fundamental
- Price
- URGN $19.44
- EE $24.49
- Analyst Decision
- URGN Strong Buy
- EE Buy
- Analyst Count
- URGN 8
- EE 7
- Target Price
- URGN $28.50
- EE $32.86
- AVG Volume (30 Days)
- URGN 1.0M
- EE 549.8K
- Earning Date
- URGN 08-07-2025
- EE 08-11-2025
- Dividend Yield
- URGN N/A
- EE 1.31%
- EPS Growth
- URGN N/A
- EE 18.98
- EPS
- URGN N/A
- EE 1.33
- Revenue
- URGN $94,238,000.00
- EE $987,637,000.00
- Revenue This Year
- URGN $39.80
- EE $34.24
- Revenue Next Year
- URGN $108.94
- EE $15.84
- P/E Ratio
- URGN N/A
- EE $18.33
- Revenue Growth
- URGN 10.85
- EE 9.86
- 52 Week Low
- URGN $3.42
- EE $17.70
- 52 Week High
- URGN $21.02
- EE $32.99
- Technical
- Relative Strength Index (RSI)
- URGN 58.49
- EE 45.64
- Support Level
- URGN $18.65
- EE $23.28
- Resistance Level
- URGN $20.11
- EE $24.91
- Average True Range (ATR)
- URGN 1.20
- EE 0.91
- MACD
- URGN -0.24
- EE 0.14
- Stochastic Oscillator
- URGN 60.08
- EE 83.36
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.